Current trends in essential thrombocythaemia

British Journal of Haematology

Volumn 117, Issue 4, 2002, Pages 796-808

  Harrison, Claire N ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

ET; Management; Pathogenesis; Prognosis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BETA THROMBOGLOBULIN; BUSULFAN; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYUREA; PHOSPHOLIPID ANTIBODY; RAS PROTEIN; SMAD PROTEIN; SMAD4 PROTEIN; THROMBOCYTE FACTOR 4; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR C MPL; TICLOPIDINE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ANEMIA; BLEEDING; BONE MARROW BIOPSY; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG ACTIVITY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MEGAKARYOCYTE; MYELOFIBROSIS; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; TUMOR SUPPRESSOR GENE;

ACUTE DISEASE; ASPIRIN; BONE MARROW EXAMINATION; CLONE CELLS; DOSAGE COMPENSATION, GENETIC; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LEUKEMIA, MYELOID; MYELOFIBROSIS; ONCOGENES; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 0036078654     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03474.x     Document Type: Review

References (122)

1. Lack of pathogenic mutations in the 5′UTR of the thrombopoietin gene in patients with non-familial essential thrombocythaemia
2. Anagrelide. A therapy for thrombocythaemic states: Experience in 577 patients
3. Leukemic transformation of essential thrombocythaemia without previous cytoreductive treatment
4. Prognostic significance of bone marrow biopsy in essential thrombocythemia
5. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor in essential thrombocythaemia
6. Pregnancy in essential thrombocythaemia: Treatment and outcome of 17 pregnancies
7. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia
8. Primary thrombocythaemia in pregnancy
9. Essential thrombocythemias. Clinical evolutionary and biological data
10. Outcome analysis of 34 pregnancies in women with essential thrombocythemia
11. Major vascular complications in essential thrombocythaemia: A study of the predictive factors in a series of 148 patients
12. Acquired von Willebrand's disease in the myeloproliferative syndrome
13. Thrombopoietin levels in patients with primary and reactive thrombocytosis
14. Clonal haemopoiesis in normal elderly women: Implications for the myeloproliferative disorders and myelodysplastic syndromes
15. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia
16. Essential thrombocythemia in pregnancy: Platelet count and pregnancy outcome
17. Management of essential thrombocythaemia during pregnancy
18. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
19. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
20. The effect of hydroxyurea in sickle cell disease: A European registry of benefits and toxicity
21. Autonomous growth of megakaryocyte progenitors in essential thrombocythaemia is not due to a mutation of c-Mpl
22. Treatment of essential thrombocythaemia during pregnancy with interferon alpha
23. Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets
24. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia
25. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction
26. Haemorrhagische thrombocythamie bei vascularer schrumpfmilz
27. Essential thrombocythemia associated with recurrent abortions and fetal growth retardation
28. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders
29. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell
30. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes
31. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long term follow-up of a randomized clinical trial
32. Regulation of platelet production: 'Thrombopoietin'
33. Genetic lesions associated with blastic transformation of polycythemia vera and essential thrombocythemia
34. Interpretation of X-chromosome inactivation patterns
35. Tissue specificity of X-chromosome inactivation patterns
36. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age
37. Platelet consumption in thrombocythemia complicated by erythromelalgia: Reversal by aspirin
38. Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin
39. Chemokine regulation of human megakaryocytopoiesis
40. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene
41. Interferon in essential thrombocythaemia
42. Homocysteine levels in polycythaemia vera and essential thrombocythaemia
43. Essential thrombocythaemia and pregnancy
44. Aspirin in essential thrombocythaemia: Status Quo and Quo Vadis
45. The pathogenesis of myelofibrosis in myeloproliferative disorders
46. Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome. A multicentric study of 55 patients
47. Haemorrhagic thrombocythaemia. A critical review
48. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: Comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic purpura
49. Acquired DNA mutations associated with in vivo hydroxyurea exposure
50. Essential thrombocythaemia and antiphospholipid antibodies
51. The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia
52. Evaluation of risk factors for thrombosis in patients with essential thrombocythaemia
53. A large proportion of patients with a diagnosis of essential thrombocythaemia do not have a clonal disorder and may be at lower risk of thrombotic complications
54. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value
55. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia
56. Familial thrombocytosis associated with overproduction of thrombopoietin due to a novel splice donor site mutation
57. Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: Diagnostic value and correlation to complications
58. Successful pregnancies after recurrent abortions in mild essential thrombocythemia
59. Study of the thrombopoietin receptor in essential thrombocythemia
60. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene
61. Translocation t(4:6) (q21:q27) in a case of primary thrombocythaemia in transformation
62. Increased frequency of genetic thrombophilia in women with complications of pregnancy
63. Decrease of SMAD4 gene expression in patients with Essential Thrombocythaemia - An escape from suppression of megak-aryopoiesis by TGF-b
64. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit
65. Controlled and uncontrolled throm-bocytosis its clinical role in essential thrombocythaemia
66. 9/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages
67. Analysis of the thrombopoietin receptor (mpl) on platelets from normal and essential thrombocythemic patients
68. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia
69. Different outcomes of pregnancy in women with essential thrombocytosis
70. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease
71. Reversal of myelofibrosis by hydroxyurea
72. Hemostatic complications and role of aspirin in myeloproliferative disorders: Results of long term follow up of 394 patients
73. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis
74. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans
75. Primary thrombocythemia in pregnancy: A report of two cases
76. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-95
77. Essential thrombocythaemia is not associated with postpartum thrombosis or an increased risk of venous thromboembolism
78. Transient neurologic and ocular manifestations in primary thrombocythemia
79. Clinical manifestations of essential thrombocythemia in young adults
80. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera
81. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera
82. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment
83. p53 tumour suppressor gene and RAS oncogenes: Molecular analysis in the chronic and leukaemic phases of essential thrombocythaemia
84. Mutation of the type II TGF-b receptor gene in patients with Essential Thrombocythaemia may cause an escape from suppression of megakaryopoi-esis by TGF-b
85. Platelet activation and thrombosis: Studies in a patient with essential thrombocythemia
86. Primary haemorrhagic thrombocythaemia
87. Primary thrombocythemia and pregnancy: Treatment and outcome in fifteen cases
88. The management of 'low-risk' and 'inter-mediate-risk' patients with primary thrombocythaemia
89. Thrombopoietin measurement in thrombocytosis: Dysregulation and lack of feedback inhibition in essential thrombocythaemia
90. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
91. Essential thrombocythemia in young adults: Major thrombotic complications and complications during pregnancy - A follow-up study in 68 patients
92. Recurrent miscarriage
93. Thrombotic complications in essential thrombocythaemia with relatively low platelet counts
94. Factor V Leiden mutation is possibly an additional risk factor for venous thromboembolism in essential thrombocythaemia and polycythaemia vera
95. Life expectancy of patients with chronic non-leukemia myeloproliferative disorders
96. No treatment for low-risk thrombocythaemia: Results from a prospective study
97. 9/L
98. Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity
99. Three successful pregnancies in a woman with essential thrombocythemia
100. Bleeding and thrombosis in the myeloproliferative disorders
101. Thrombocythaemia and coronary artery disease
102. Transient normal platelet counts and decreased requirement for interferon during pregnancy in essential thrombocythaemia
103. Treatment of essential thrombocythemia with anagrelide
104. Thrombocythaemia and recurrent late abortions: Normal outcome of pregnancies after antiaggregatory treatment, Case report
105. Pregnancy in patients with essential thrombocythemia. Three cases
106. The effects of anagrelide on human megakaryocytopoiesis
107. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors
108. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion
109. Long-term use of anagrelide in young patients with essential thrombocythaemia
110. Mutations in the TGFbRII gene are unlikely to be responsible for the reduced sensitivity to TGFb in megakaryocytes from patients with essential thrombocythaemia
111. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders
112. Adverse effects of antiaggregating platelet therapy in the treatment of polycythaemia vera
113. Failure to show molecular evidence for involvement of thrombopoietin and c-Mpl genes in essential thrombocythaemia
114. A clinical update in polycythaemia vera and essential thrombocythaemia
115. A long-term retrospective study of young women with essential thrombocythaemia
116. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis
117. Primary thrombocythaemia treated with busulphan
118. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias
119. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia
120. Postpartum thrombosis in primary thrombocythaemia
121. A single institutional experience with 43 pregnancies in essential thrombocythemia
122. Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor beta 1, produced in normal amount, in patients with essential thrombocythaemia